Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766328 | 1.00 | NPC1 (0.50) | NPC1RAB9AALDH1A1THRBCYP2C9 | |
| SCHEMBL17943265 | 1.00 | NPC1 (0.50) | NPC1RAB9AALDH1A1THRBCYP2C9 | |
| SCHEMBL16171796 | 0.92 | MME (0.54) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL12411242 | 0.92 | MME (0.54) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL14009993 | 0.92 | MME (0.54) | ALDH1A1MMEACECPA1ACE2 | |
| SCHEMBL27271007 | 0.89 | ALDH1A1 (0.50) | NPC1RAB9AALDH1A1THRBCYP2C9 | |
| SCHEMBL14009996 | 0.88 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1MMEACE | |
| SCHEMBL12411244 | 0.88 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1MMEACE | |
| SCHEMBL123574 | 0.86 | MME (0.58) | NPC1RAB9AMMEACECPA1 | |
| SCHEMBL15592756 | 0.86 | MME (0.58) | NPC1RAB9AMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023222558-A1 | PRECURSOR AND THERANOSTIC RADIOTRACER WITH IMPROVED TUMOR RETENTION | ZOUNEK ALEXIS NIKOLAI (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230331640-A1 | PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUND | OSAKA UNIVERSITY (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731917-B2 | Production method for radiolabeled aryl compound | OSAKA UNIVERSITY (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | NORTHWEST UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| US-8377865-B2 | Peptidomimetics ; determine ability to bind to growth hormone secretagogue; ghrelin antagonist; appetite stimulation; dietetics ; weight maintenance; eating disorders | IPSEN PHARMA S.A.S. (FR) | 2013-02-19 | — | — | US | disclosed |
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | LIPOTEC, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
| US-7456253-B2 | Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2008-11-25 | — | — | US | disclosed |
| US-20080242619-A1 | Growth hormone releasing peptides | BIOMEASURE, INCORPORATED | 2008-10-02 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | NPC1 1118/4885RAB9A 2323/4885ALDH1A1 3319/4885 |
| US-20230331640-A1 | PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUND | NAT1, CAT, ARSA | NPC1 749/4885RAB9A 621/4885ALDH1A1 817/4885 |
| US-11731917-B2 | Production method for radiolabeled aryl compound | NAT1, CAT, ARSA | NPC1 749/4885RAB9A 621/4885ALDH1A1 817/4885 |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | NPC1 3716/4885RAB9A 4768/4885ALDH1A1 4708/4885 |
| US-20080242619-A1 | Growth hormone releasing peptides | GHRHR, THRB, PRLHR | NPC1 4192/4885RAB9A 2648/4885ALDH1A1 3712/4885 |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | VIP, PREP, ACE | NPC1 1394/4885RAB9A 3258/4885ALDH1A1 3275/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | NPC1 4400/4885RAB9A 3781/4885ALDH1A1 3689/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | NPC1 777/4885RAB9A 1780/4885ALDH1A1 3256/4885 |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | NPC1 617/4885RAB9A 3909/4885ALDH1A1 2824/4885 |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | ATP2A3, MYLK2, MYL6 | NPC1 4780/4885RAB9A 2734/4885ALDH1A1 4258/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | NPC1 2004/4885RAB9A 1579/4885ALDH1A1 4019/4885 |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | HDAC5, HDAC6, HDAC3 | NPC1 1381/4885RAB9A 2546/4885ALDH1A1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.